Lightfoot Courtney J, Wilkinson Thomas J, Sohansoha Gurneet K, Gillies Clare L, Vadaszy Noemi, Ford Ella C, Davies Melanie J, Yates Thomas, Smith Alice C, Graham-Brown Matthew P M
Leicester Kidney Lifestyle Team, Department of Population Health Sciences, University of Leicester, Leicester, UK.
NIHR Leicester Biomedical Research Centre, Leicester, UK.
NPJ Digit Med. 2024 Nov 12;7(1):318. doi: 10.1038/s41746-024-01296-1.
My Kidneys & Me (MK&M), a digital health intervention delivering specialist health and lifestyle education for people with CKD, was developed and its effects tested (SMILE-K trial, ISRCTN18314195, 18/12/2020). 420 adult patients with CKD stages 3-4 were recruited and randomised 2:1 to intervention (MK&M) (n = 280) or control (n = 140) groups. Outcomes, including Patient Activation Measure (PAM-13), were collected at baseline and 20 weeks. Complete case (CC) and per-protocol (PP) analyses were conducted. 210 (75%) participants used MK&M more than once. PAM-13 increased at 20 weeks compared to control (CC: +3.1 (95%CI: -0.2 to 6.4), P = 0.065; PP: +3.6 (95%CI: 0.2 to 7.0), P = 0.041). In those with low activation at baseline, significant between-group differences were observed (CC: +6.6 (95%CI: 1.3 to 11.9), P = 0.016; PP: +9.2 (95%CI: 4.0 to 14.6), P < 0.001) favouring MK&M group. MK&M improved patient activation in those who used the resource compared to standard care, although the overall effect was non-significant. The greatest benefits were seen in those with low activation.
“我的肾脏与我”(MK&M)是一种数字健康干预措施,为慢性肾脏病患者提供专业的健康和生活方式教育。该措施已研发完成并对其效果进行了测试(SMILE-K试验,ISRCTN18314195,2020年12月18日)。招募了420名3 - 4期成年慢性肾脏病患者,并按2:1随机分为干预组(MK&M)(n = 280)和对照组(n = 140)。在基线和20周时收集包括患者激活量表(PAM - 13)在内的结果。进行了完全病例(CC)分析和符合方案(PP)分析。210名(75%)参与者不止一次使用MK&M。与对照组相比,干预组在20周时PAM - 13有所增加(CC分析:增加3.1(95%置信区间:-0.2至6.4),P = 0.065;PP分析:增加3.6(95%置信区间:0.2至7.0),P = 0.041)。在基线时激活水平较低的患者中,观察到组间存在显著差异(CC分析:增加6.6(95%置信区间:1.3至11.9),P = 0.016;PP分析:增加9.2(95%置信区间:4.0至14.6),P < 0.001),干预组更具优势。与标准护理相比,MK&M改善了使用该资源的患者的激活情况,尽管总体效果不显著。激活水平较低的患者受益最大。